Skip to main content

Starlix Side Effects

Generic name: nateglinide

Medically reviewed by Last updated on Jan 21, 2024.

Note: This document contains side effect information about nateglinide. Some dosage forms listed on this page may not apply to the brand name Starlix.

Applies to nateglinide: oral tablet.

Serious side effects of Starlix

Along with its needed effects, nateglinide (the active ingredient contained in Starlix) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking nateglinide:

More common

Less common

Incidence not known

Other side effects of Starlix

Some side effects of nateglinide may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

incidence not known

For Healthcare Professionals

Applies to nateglinide: oral tablet.


The most frequently reported adverse events included upper respiratory tract infections and symptoms of hypoglycemia.[Ref]


Common (1% to 10%): Hypoglycemia

Frequency not reported: Increases in mean uric acid level[Ref]

Hypoglycemia has been reported and has generally been mild and corrected by intake of carbohydrates. In comparative clinical trials, hypoglycemia was reported in 10.4%, 14.5%, 6.9%, 19.8%, and 4.1% in patients receiving nateglinide alone, nateglinide plus metformin, metformin alone, glyburide alone, and placebo, respectively.

Mean uric acid levels were increased in patient receiving this drug as monotherapy. The difference from placebo in treated patients was 0.29 mg/dL, 0.45 mg/dL, 0.28 mg/dL, and 0.19 mg/dL in patients receiving nateglinide alone, nateglinide plus metformin, metformin alone, glyburide alone, respectively. The clinical significance of these findings is unknown.[Ref]


Common (1% to 10%): Upper respiratory tract infection, bronchitis, coughing[Ref]


Postmarketing reports: Hypersensitivity reactions such as rash, itching, and urticaria[Ref]


Common (1% to 10%): Diarrhea, abdominal pain, dyspepsia, nausea

Uncommon (0.1% to 1%): Vomiting[Ref]

Gastrointestinal symptoms, especially diarrhea and nausea, were no more common in patients using this drug in combination with metformin than in patients receiving metformin alone.[Ref]


Postmarketing reports: Elevated liver enzymes, jaundice, cholestatic hepatitis[Ref]

Nervous system

Common (1% to 10%): Dizziness[Ref]


Common (1% to 10%): Back pain, arthropathy[Ref]


Frequency not reported: Peripheral edema[Ref]

Peripheral edema was no more common in patients using this drug in combination with rosiglitazone than in patients receiving rosiglitazone alone.[Ref]


Postmarketing reports: Erythema multiforme[Ref]


Common (1% to 10%): Flu symptoms[Ref]


Common (1% to 10%): Accidental trauma[Ref]


1. (2001) "Product Information. Starlix (nateglinide)." Novartis Pharmaceuticals

2. Cerner Multum, Inc. "UK Summary of Product Characteristics."

3. Cerner Multum, Inc. "Australian Product Information."

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.